Last updated on July 2017

Multicentre Randomised Phase III Study of the Efficacy and Safety of Hetrombopag Olamine in Idiopathic Thrombocytopenic Purpura (ITP) Patient

Brief description of study

A multicentre, randomised, double-blind,4-stages phase III study enrolled 414 patients with chronic, previously treated ITP. Dosage could be adjusted (2.5~.75 mg/day) to maintain platelet counts 50~250×109/L

Clinical Study Identifier: NCT03222843


Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Yu Hu, Ph.D

Union Hospital Tongji Medical College Huazhong University of Science and technology
Wuhan, China
  Connect »

Ting Niu, MD

West China Hospital Sichuan University
Chengdu, China
  Connect »

Renchi Yang, MD

Hospital of Blood Diseases, Chinese Academy of Medical Sciences
Tianjin, China
  Connect »